Cefditoren pivoxil:a new antibiotic for the treatment of respiratory infections
Antibiotic Update: A focus on respiratory infections · Antibiotic Update: A focus on respiratory...
Transcript of Antibiotic Update: A focus on respiratory infections · Antibiotic Update: A focus on respiratory...
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates 1
Margaret Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP
President, Fitzgerald Health Education Associates,
North Andover, MAFamily Nurse Practitioner,
Greater Lawrence (MA) Family Health CenterEditorial Board Member
The Nurse Practitioner Journal, The Prescriber’s Letter, American Nurse Today
Member, Pharmacy and Therapeutics CommitteeNeighborhood Health Plan, Boston, MA
Disclosure
• No real or potential conflict of interest to disclose
• No off-label, experimental or investigational use of drugs or devices will be presented.
Fitzgerald Health Education Associates 2
Objectives
• Having completed the learning activities, the participant will be able to:– Identify the most likely pathogens
causing commonly encountered bacterial upper and lower tract infections.
Fitzgerald Health Education Associates 3
Objectives(continued)
• Having completed the learning activities, the participant will be able to: (cont.)– Describe recommendations found in
current guidelines for the treatment of the aforementioned infections.
– Explore methods to minimize antimicrobial resistance.
Fitzgerald Health Education Associates 4
Are the bugs winning?Is this a new problem?
Fitzgerald Health Education Associates 5 Fitzgerald Health Education Associates 6
Source: http://www.pbs.org/newshour/rundown/mutating-gonorrhea-superbugs-coming-soon-to-a-town-near-you/
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
1
What facilitates resistance?
• Time• Exposure
– Unnecessary doses– Long tx period
• Where is the evidence?
• Under dosing– Leaves behind more
resistant bugs
Fitzgerald Health Education Associates 77
Resources
• Antimicrobial resistance and prudent prescribing– www.cdc.gov/drugresistance– www.cdc.gov/getsmart– www.cdc.gov/vitalsigns– The Sanford Guide to Antimicrobial
Therapy 2017 47th edition
Fitzgerald Health Education Associates 9
What is one of themost challenging visits?
The viral illness where no antimicrobial is dispensed.
Antibiotic Prescriptions Associated with Increased Patient Satisfaction
with Emergency Department Visits for Acute RTI
• Conclusions– Antibiotic prescriptions are associated with
increased overall patient satisfaction in non-VA, but not VA, ED visits for URIs. Continued efforts to reduce unnecessary prescriptions in these settings must address ways to maintain patient satisfaction and still reduce antibiotic prescriptions.
Fitzgerald Health Education Associates 11
RTI Article
Source: http://onlinelibrary.wiley.com/doi/10.111
1/j.1553-2712.2009.00522.x/full
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
2
Br J Gen Pract. 2016 Jan; 66(642): e40–e46.
• Conclusion– “Patients were less satisfied in practices
with frugal antibiotic prescribing. A cautious approach to antibiotic prescribing can require a trade-off in terms of patient satisfaction.”
– Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4684034/
Fitzgerald Health Education Associates 13
Br J Gen Pract. 2016 Jan; 66(642): e40–e46.
(continued)
• “GPs who wish to play their part in addressing issues of antibiotic resistance will need to consider alternatives to an antibiotic prescription that do not compromise patient satisfaction.”
Fitzgerald Health Education Associates 14
True or false?
• In a study of antimicrobial prescribing among primary care providers, clinicians in high volume practices and those who were in practice longer were more likely to prescribe antibiotics inappropriately.
– Source: CMAJ • October 9, 2007; 177 (8).
Fitzgerald Health Education Associates 1515
My View
• An entire generation of people– Inappropriately
overprescribed antimicrobials by ill-informed healthcare providers
– A vexing problem with resistant pathogens
Fitzgerald Health Education Associates 17
CDC RecommendationsReducing Inappropriate Antimicrobial Prescribing
• Build cooperation and trust.– Convey a sense of partnership and
message of hope.• “Usually the 3rd day is the worst. Likely you
are going to start feeling better shortly.”
– Verbalize, “the good news is, you do not need an antibiotic!”
Fitzgerald Health Education Associates 18
This is also “only a virus.”
• Avoid dismissive statements.– “Illness is going around.”– “Only a viral infection.”
Fitzgerald Health Education Associates 19
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
3
CDC
• Be confident with recommendation to use symptomatic and other therapies aside from antibiotics. – Analgesics– Decongestants– Others
• Consider providing “care packages” with nonantibiotic therapies.
Fitzgerald Health Education Associates 20
CDC (continued)
• Encourage active management of the illness. – Be specific on the normative course of
illness, when to return for worsening signs or symptoms.
• Emphasize the importance of adequate nutrition and hydration.
– Source: http://www.cdc.gov/getsmart/campaign-materials/pediatric-treatment.html
Fitzgerald Health Education Associates 21
CDC Recommendations
• Reducing inappropriate antimicrobial prescribing– http://www.cdc.gov/getsm
art/campaign-materials/info-sheets/adult-approp-summary.html
Fitzgerald Health Education Associates 22
Empiric Antimicrobial Therapy
• The decision-making process where the clinician chooses the agent based on patient characteristics and site of infection.
Fitzgerald Health Education Associates 2323
Questions to Ask Prior to Choosing an Antimicrobial
• What is/are the most likely pathogen(s) causing this infection?
• What is the spectrum of a given antimicrobial’s activity?
• What is the likelihood of resistant pathogen?
Fitzgerald Health Education Associates 2424
Questions to Ask Prior to Choosing an Antimicrobial
(continued)• What is the danger if there is
treatment failure? • What is the optimal safe
antimicrobial dose?• What is the duration of the shortest
but effective course of therapy?
Fitzgerald Health Education Associates 25
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
4
True or false?
• The recommended length of community acquired pneumonia (CAP) therapy is a minimum of 5 days with evidence of increasing stability, afebrile for 48–72 h prior to antimicrobial discontinuation.
– Source: Mandell, L. et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-acquired Pneumonia in Adults. Clin Infect Dis.;44:S21-S72. Available at https://www.thoracic.org/statements/resources/mtpi/idsaats-cap.pdf
Fitzgerald Health Education Associates 26
“The antibiotic course has had its day.”
• “…the idea that stopping antibiotic treatment early encourages antibiotic resistance is not supported by evidence, while taking antibiotics for longer than necessary increases the risk of resistance. Far from being irresponsible, shortening the duration of a course of antibiotics might make antibiotic resistance less likely.”
– Source: http://www.bmj.com/content/358/bmj.j3418
Fitzgerald Health Education Associates 27
True or false?
The majority of bacterial infections seen in the outpatient setting are caused by resistant pathogens?
Fitzgerald Health Education Associates 28
Example of Antibiogram
No ED isolates. For teaching purposes only.29Fitzgerald Health Education Associates
Antimicrobial StewardshipAvoid prescribing antimicrobials when there is less-than-robust
evidence for use.
Number Needed to Treat
• Defined– The number of patients that need to be
treated for one of them to benefit compared with a control in a clinical trial
• A perfect clinical trial, where all benefited from the treatment=NNT=1
– Source: http://clincalc.com/stats/nnt.aspxhttp://www.thennt.com/thennt-explained/
Fitzgerald Health Education Associates 31
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
5
Is antimicrobial neededin ABRS therapy?
• Meta-analyses of antibiotic treatment vs. placebo in ABRS– Number needed to treat (NNT) 95% CI
• In adults=13 (9–22)• In children=5 (4–15)
– Source: Chow, A., et al., IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults
Fitzgerald Health Education Associates 3232
True or false?
One of the most compelling indications for the use of a respiratory fluoroquinolone (levofloxacin, moxifloxacin) is the treatment
of infection caused by drug-resistant S. pneumoniae.
33Fitzgerald Health Education Associates
FDA Warning FQ Use http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm
• “…the serious adverse effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections who have other treatment options. For patients with these conditions, fluoroquinolones should be reserved for those who do not have alternative treatment options.”
Fitzgerald Health Education Associates 34
FDA Warning FQ Use http://www.fda.gov/Drugs/DrugSafety/ucm500143.htm
(continued)• “FDA safety review has shown that
fluoroquinolones when used systemically (i.e., tablets, capsules, and injectable) are associated with disabling and potentially permanent serious adverse effects that can occur together. These adverse effects can involve the tendons, muscles, joints, nerves, and central nervous system.”
Fitzgerald Health Education Associates 35
Global Initiative for Chronic Obstructive Lung Disease
National Heart, Lung, and Blood Institute
NIH
World Health Organization
www.goldcopd.org
Fitzgerald Health Education Associates 36
Exacerbation Definition, Evaluation and Treatment
• An exacerbation of COPD is an event in the natural course of the disease characterized by a change in the patient’s baseline dyspnea, cough, and/or sputum beyond day-to-day variability sufficient to warrant a change in management.
Fitzgerald Health Education Associates 37
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
6
Treatment of COPD Exacerbation
Use of bronchodilators
Short-acting beta2-agonist and/or muscarinic antagonist (ipratropium bromide) PRNConsider adding long-acting bronchodilator (LABA, LAAM (salmeterol, formoterol, tiotropium bromide) if patient currently not using one.
If baseline FEV1<50% of
predicted
Add a systemic corticosteroid such as prednisone 40 mg/d for 5-10 days. Recent study supports shorter (5 day) course equally effective with fewer adverse effects than longer (10 day) course. Consider adding inhaled corticosteroid if not currently using.
Encourage smoking cessation
Smoking cessation is associated with COPD exacerbation reduction and reduction in rate of loss of lung function.
Antimicrobial therapy in COPD
exacerbation
Likely indicated in the presence of 3 cardinal symptoms: Increased dyspnea, increased sputum volume, and increased sputum purulence, though evidence varies.
Fitzgerald Health Education Associates 38
Use of bronchodilators
Short-acting beta2-agonist (albuterol) and/or muscarinic antagonist (ipratropium bromide) PRNConsider adding long-acting bronchodilator (LABA, [salmeterol], LAMA [tiotropium bromide]) if patient currently not using one.
Treatment of COPD Exacerbation
Use of bronchodilators
Short-acting beta2-agonist and/or muscarinic antagonist (ipratropium bromide) PRNConsider adding long-acting bronchodilator (LABA, LAAM (salmeterol, formoterol, tiotropium bromide) if patient currently not using one.
If baseline FEV1<50% of
predicted
Add a systemic corticosteroid such as prednisone 40 mg/d for 5-10 days. Recent study supports shorter (5 day) course equally effective with fewer adverse effects than longer (10 day) course. Consider adding inhaled corticosteroid if not currently using.
Encourage smoking cessation.
Smoking cessation is associated with COPD exacerbation reduction and reduction in rate of loss of lung function.
Antimicrobial therapy in COPD
exacerbation
Likely indicated in the presence of 3 cardinal symptoms: Increased dyspnea, increased sputum volume, and increased sputum purulence, though evidence varies.
Fitzgerald Health Education Associates 39
If baseline FEV1<50% of predicted
Add a systemic corticosteroid such as prednisone 40 mg/d PO for 5–10 days. Recent study supports shorter (5-day) course equally effective with fewer adverse effects than longer (10-day) course. Consider adding inhaled corticosteroid if not currently using.
Treatment of COPD Exacerbation
Use of bronchodilators
Short-acting beta2-agonist and/or muscarinic antagonist (ipratropium bromide) PRNConsider adding long-acting bronchodilator (LABA, LAAM (salmeterol, formoterol, tiotropium bromide) if patient currently not using one.
If baseline FEV1<50% of
predicted
Add a systemic corticosteroid such as prednisone 40 mg/d for 5-10 days. Recent study supports shorter (5 day) course equally effective with fewer adverse effects than longer (10 day) course. Consider adding inhaled corticosteroid if not currently using.
Encourage smoking cessation
Smoking cessation is associated with COPD exacerbation reduction and reduction in rate of loss of lung function.
Antimicrobial therapy in COPD
exacerbation
Likely indicated in the presence of 3 cardinal symptoms: Increased dyspnea, increased sputum volume, and increased sputum purulence, though evidence varies.
Fitzgerald Health Education Associates 40
Encourage smoking cessation
Smoking cessation is associated with COPD exacerbation reduction and reduction in rate of loss of lung function.
Treatment of COPD Exacerbation
Use of bronchodilators
Short-acting beta2-agonist and/or muscarinic antagonist (ipratropium bromide) PRNConsider adding long-acting bronchodilator (LABA, LAAM (salmeterol, formoterol, tiotropium bromide) if patient currently not using one.
If baseline FEV1<50% of
predicted
Add a systemic corticosteroid such as prednisone 40 mg/d for 5-10 days. Recent study supports shorter (5 day) course equally effective with fewer adverse effects than longer (10 day) course. Consider adding inhaled corticosteroid if not currently using.
Encourage smoking cessation
Smoking cessation is associated with COPD exacerbation reduction and reduction in rate of loss of lung function.
Antimicrobial therapy in COPD
exacerbation
Likely indicated in the presence of 3 cardinal symptoms: Increased dyspnea, increased sputum volume, and increased sputum purulence, though evidence varies.
Fitzgerald Health Education Associates 41
Antimicrobial therapy in COPD exacerbation
Likely indicated in the presence of 3 cardinal symptoms: Increased dyspnea, increased sputum volume, and increased sputum purulence, though evidence varies.
Match each medication with the warning associated.
Fitzgerald Health Education Associates 42
Potentially associated with QT prolongation and increased risk of CV death during use, particularly in those with highest CV riskPotential tendon rupture, particularly when taken with systemic corticosteroid in an older adult
Antimicrobial Therapy in COPD Flare
• Aside from bacterial infection, tobacco use, air pollution, and viruses are common contributing factors to COPD flare.
Fitzgerald Health Education Associates 43
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
7
Antimicrobial Therapy in COPD Flare
(continued)
• Causative bacterial pathogens (30–50%) include select Gram-negative (Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis) and Gram-positive (Streptococcus pneumoniae) pathogens.– Less common pathogens include atypical
pathogens, other Gram-positive and -negative organisms.
Fitzgerald Health Education Associates 44
Bacterial Pathogens Associated with COPD Flare
• Haemophilus influenzae– Gram-negative
rod-shaped bacterium– ~30% beta-lactamase
production rate nationwide– Nontypable strains
contribute to COPD flare
Fitzgerald Health Education Associates 4545
Bacterial Pathogens Associated with COPD Flare
(continued)• Streptococcus pneumoniae
– Gram-positive diplococci– DRSP rate nationally=25%
Fitzgerald Health Education Associates 4646
Image source: https://commons.wikimedia.org/wiki/File:Pneumococcus_CDC_PHIL_ID1003.jpg
True or false?
• According to the CDC, up to 70% of healthy adults are carrying S. pneumoniae bacteria at any given time.
Fitzgerald Health Education Associates 47
Bacterial Pathogens Associated with COPD Flare
(continued)
• Moraxella catarrhalis– Gram-negative with ≥90% beta-lactamase production rate
Fitzgerald Health Education Associates 4848
Mild to moderate COPD exacerbation/acute exacerbation of chronic bronchitisAntimicrobial therapy usually not indicated. If prescribed, consider spectrum of antimicrobial activity with each product.
If prescribed, consider using the following agents─Amoxicillin─TMP-SMX ─Doxycycline
More severe COPD exacerbation/acute exacerbation of chronic bronchitis Role of antimicrobial therapy debated even for severe disease. If prescribed, consider spectrum of antimicrobial activity and benefit vs risk ratio with each product. Consider severity of COPD and comorbidities in decision-making process.
Use one of the following agents:─Beta-lactam
o Amoxicillin-clavulanateo Cephalosporin (cefdinir,
cefpodoxime, others)─Macrolide
o Azithromycino Clarithromycin
─Respiratory fluoroquinolone ─Moxi-, levofloxacin
Mild to moderate COPD exacerbationAntimicrobial therapy usually not indicated. If prescribed, consider spectrum of antimicrobial activity with each product.
If prescribed, one of the following─Amoxicillin
─Lacks stability in presence of beta-lactamase
─TMP-SMX ─1 in 4 treatment failure rate
─Doxycycline─Effective against non resistant S. pneumoniae, pertinent Gram negs, stable in presence beta-lactamase
Fitzgerald Health Education Associates 49
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
8
Mild to moderate COPD exacerbation/acute exacerbation of chronic bronchitisAntimicrobial therapy usually not indicated. If prescribed, consider spectrum of antimicrobial activity with each product.
If prescribed, consider using the following agents─Amoxicillin─TMP-SMX ─Doxycycline
More severe COPD exacerbation/acute exacerbation of chronic bronchitis Role of antimicrobial therapy debated even for severe disease. If prescribed, consider spectrum of antimicrobial activity and benefit vs risk ratio with each product. Consider severity of COPD and comorbidities in decision-making process.
Use one of the following agents:─Beta-lactam
o Amoxicillin-clavulanateo Cephalosporin (cefdinir,
cefpodoxime, others)─Macrolide
o Azithromycino Clarithromycin
─Respiratory fluoroquinolone ─Moxi-, levofloxacin
More severe COPD exacerbation/acute exacerbation of chronic bronchitis Role of antimicrobial therapy debated even for severe disease. If prescribed, consider spectrum of antimicrobial activity and benefit vs. risk ratio with each product including drug interactions. Consider severity of COPD and comorbidities in decision-making process.
Fitzgerald Health Education Associates 50
Mild to moderate COPD exacerbation/acute exacerbation of chronic bronchitisAntimicrobial therapy usually not indicated. If prescribed, consider spectrum of antimicrobial activity with each product.
If prescribed, consider using the following agents─Amoxicillin─TMP-SMX ─Doxycycline
More severe COPD exacerbation/acute exacerbation of chronic bronchitis Role of antimicrobial therapy debated even for severe disease. If prescribed, consider spectrum of antimicrobial activity and benefit vs. risk ratio with each product. Consider severity of COPD and comorbidities in decision-making process.
Use one of the following agents:─Beta-lactam
o Amoxicillin-clavulanateo Cephalosporin (cefdinir,
cefpodoxime, others)─Macrolide
o Azithromycino Clarithromycin
─Respiratory fluoroquinolone ─Moxi-, levofloxacin
Use one of the following agents•Beta-lactam
– Amoxicillin-clavulanate– Cephalosporin (cefdinir, cefpodoxime, others)
•Macrolide– Azithromycin– Clarithromycin
•Respiratory fluoroquinolone – Moxi-, levofloxacin
Fitzgerald Health Education Associates 51
Antibiotics for Acute COPD Exacerbations: The NNT
(But based on older meta-analysis, might overestimate helpfulness.)
1 in 8 were helped (life saved)1 in 3 were helped (preventing failed treatment)
1 in 20 were harmed (diarrhea)
Source: http://www.thennt.com/nnt/antibiotics-for-copd-exacerbation/
True or false?
• The diagnosis of acute bronchitis is usually limited to those without chronic airway disease (e.g., asthma or COPD).
Fitzgerald Health Education Associates 53
TRUE
Cough associated with acute bronchitis can typically last up to:
A. 1 week. B. 2 weeks. C. 3 weeks. D. 3 months.
Fitzgerald Health Education Associates 54
• Which of the following is the most common pathogen implicated in acute bronchitis?
Fitzgerald Health Education Associates 56
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
9
A. S. pneumoniaeB. H. influenzaeC. M. pneumoniaeD. Respiratory virus
Fitzgerald Health Education Associates 57
Acute Bronchitis Likely causative pathogens
Organism % Comment
Respiratory tract viruses
Consider using anticholinergic bronchodilator, such as ipratropium bromide (Atrovent®), inhaled beta2-agonist, such as albuterol.
Fitzgerald Health Education Associates 59
ACCP Recommendations
• For severe paroxysms of post-infectious cough, consider prescribing 30 to 40 mg of prednisone per day for a short, finite period of time when other common causes of cough including rhinosinusitis, asthma, or gastroesophageal reflux disease have been ruled out.
– Source: http://journal.chestnet.org/article/S0012-3692(15)52825-0/fulltext
Fitzgerald Health Education Associates 60
Acute BronchitisLikely Causative Pathogens
Organism % CommentBacterial pathogens, such as M. pneumoniae, C. pneumoniae, B. pertussis
Consider use of macrolide or tetracycline form such as doxycycline when antimicrobial therapy indicated.
Fitzgerald Health Education Associates 61
Source: https://www.sanfordguide.com/news/page/2/
Differentiation from Acute Bronchitis from Pneumonia
• Pneumonia is unlikely if all of the following are absent– Fever: ≥38°C (100.4°F)– Tachypnea: ≥24 breaths/min– Tachycardia: ≥100 beats/min– Evidence of consolidation, crackles on
chest exam
Fitzgerald Health Education Associates 62
Antimicrobial Stewardship
When antimicrobial therapy is needed, prescribe a sufficient dose.
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
10
You see an 8-year-oldwith acute otitis media.
• You determine she is a candidate for antimicrobial therapy. The child weighs 50 kg. When calculating the amoxicillin at 90 mg/kg/d, the dose exceeds 4 g per day.
Fitzgerald Health Education Associates 64
You see an 8-year-oldwith acute otitis media.
(continued)
• You consider that for this child:A. The calculated dose should
be prescribed. B. The antibiotic dose should not exceed
the recommended adult dose.
C. No more than 750 mg amoxicillin per day should be prescribed.
Fitzgerald Health Education Associates 65
Prescribing Many Antimicrobials in Pediatric Obesity
• Limited data available– Recommendations made are extrapolated
from pharmacokinetics, adult obesity data
• With the beta-lactams • Penicillins, cephalosporins
– Prescribe based on actual body weight, do not exceed adult doses
– Source: Drug Dosing for Overweight and Obese Patients, available at http://www.schn.health.nsw.gov.au/_policies/pdf/2013-7034.pdf
Fitzgerald Health Education Associates 67 Fitzgerald Health Education Associates 68
General Rule with Peds Antibiotic Dosing
• Safe products• Easily metabolized• Prescribe up to but do not exceed
adult doses– Source: Prescriber's Letter 2008; 15(4):240425.
AAP Clinical Practice Guideline: The Diagnosis and Management of
Acute Otitis Media
Source: http://pediatrics.aappublications.org
/content/131/3/e964.short
Components of AOM
• Objective findings– Bulging TM– TM erythema– Limited or absent
TM mobility– Air-fluid level
behind TM– Otorrhea
Fitzgerald Health Education Associates 70
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
11
Components of AOM (continued)
• Distinct otalgia – Discomfort clearly
referable to the ear(s) that results in interference with or precludes normal activity or sleep
Fitzgerald Health Education Associates 71
Please refer to AOM guidelines for information on “watch and wait” therapy, which involved treating
otalgia but no antibiotics, given high rate of spontaneous resolution
without antimicrobials.
Causative Organisms in Acute Bacterial Otitis Media
Overall pathogens in AOM=No pathogen (4%), bacteria plus virus (66%)
Organism CommentS. pneumoniae (Gram positive diplococci) (49%)
Consider drug-resistant S. pneumoniae riskMechanism of resistance- Alter binding sites within bacterial cellsLow rate (~10–20%) of spontaneous resolution without antimicrobial therapy
Fitzgerald Health Education Associates 73
Causative Organisms in Acute Bacterial Otitis Media
Overall pathogens in AOM=No pathogen (4%),bacteria plus virus (66%)
Organism CommentH. influenzae (Gram negative bacillus) (29%)
Resistance via beta-lactamase productionModerate rate (~50%) of spontaneous resolution without antimicrobial therapy
Fitzgerald Health Education Associates 74
Causative Organisms in Acute Bacterial Otitis Media
Overall pathogens in AOM=No pathogen (4%), virus (70%), bacteria plus virus (66%)
(continued)
Organism CommentM. catarrhalis (Gram negative cocci) (28%)
Resistance via beta-lactamase productionNearly all spontaneously resolve without antimicrobial therapy
Fitzgerald Health Education Associates 75
Temp ≥39°C
(≥102.2°F) or severe otalgia
At diagnosis for patients being treated initially with antibacterial agents OR clinically defined treatment failure at 48–72 hours after initial management with observation option
Recommended Alternative for Penicillin Allergy
No Amoxicillin 80–90 mg/kg/day in 2
divided doses
Cefdinir (14 mg/kg per day in 1 or 2 doses)
Cefuroxime (30 mg/kg per day in 2 divided doses)
Cefpodoxime (10 mg/kg per day in 2 divided doses)
Yes Amoxicillin-clavulanate90 mg/kg/day of amoxicillin
with 6.4 mg/kg/day of clavulanate [amoxicillin to
clavulanate ratio, 14:1] in 2 divided doses
Ceftriaxone (50 mg IM or IV per day for 1 or 3 d)
Recommended Antibacterial Agents in AOM
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
12
Type I Hypersensitivity Reaction
• AKA immediate or anaphylactic hypersensitivity– Reaction involves preferential production
of IgE in response to certain antigens (allergens)
Fitzgerald Health Education Associates 77
Type I Hypersensitivity Reaction (continued)
• Usually involves skin (urticaria eczema), eyes (conjunctivitis), nasopharynx (rhinorrhea, rhinitis), bronchopulmonary tissues (wheeze, cough) and/or GI tract (gastroenteritis)
Fitzgerald Health Education Associates 78
Type II Hypersensitivity
• AKA cytotoxic hypersensitivity– Antigens normally endogenous– Primarily mediated by IgM or IgG antibodies
• Reaction time– Minutes to hours
Fitzgerald Health Education Associates 79
Type II Hypersensitivity (continued)
• Clinical manifestations– Drug-induced
hemolytic anemia, granulocytopenia, thrombocytopenia
Fitzgerald Health Education Associates 80
Cross Allergy of PCN to Cephalosporins?
• How would you prescribe cephalosporins to patients with penicillin allergies? FHEA News, Volume XII, Issue VIII, Page 13– Available at
http://fhea.com/main/content/Newsletter/fheanews_volume12_issue8.pdf
Fitzgerald Health Education Associates 81
Temp≥39°C (≥102.2°F) or severe otalgia
Clinically defined treatment failure at 48–72 hours after initial management with antibacterial agentsRecommended Alternative for
penicillin allergyNo Amoxicillin-
clavulanate90 mg/kg/day of
amoxicillin component with 6.4 mg/kg/day
of clavulanate in 2 divided doses
Ceftriaxone3 days
Clindamycin (30–40 mg/kg per day in 3 divided doses),
with or without third generation cephalosporin
Yes Ceftriaxone(50 mg IM or IV for 3 d)
Clindamycin (30–40 mg/kg per day in 3 divided doses), plus third
generation cephalosporinTympanocentesis, consult specialist
Recommended Antibacterial Agents in AOM (continued)
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
13
Clindamycin Therapy in AOM
• Possible DRSP coverage– Not active against H. influenzae,
M. catarrhalis• One of the most severe adverse effects
– Clostridium difficile-associated diarrhea– Moderated risk with use of high-
quality probiotic
Fitzgerald Health Education Associates 83
Duration of Therapy in AOM
• <2 years of age– 10 d for amoxicillin-based products– Some products with FDA-approved shorter
courses as previously mentioned
• ≥2 years of age– 5–7 d for most children even with
amoxicillin-based products
Fitzgerald Health Education Associates 84
Antimicrobials Not Recommended
• Azithro-, clarithromycin– DRSP treatment failure risk
• TMP-SMX– DRSP treatment failure risk, – H. influenzae treatment failure risk
Fitzgerald Health Education Associates 85
Antimicrobial Prophylaxis in Recurrent AOM
True or false?• Per Sanford Guide, the use of antibiotics
to prevent otitis media is a major contributor to emergence of antibiotic-resistant S. pneumoniae.
– Source: Gilbert, D., Moellering, R., Eliopoulos, G., Chambers, H., Saag, M. (2017) The Sanford Guide to Antimicrobial Therapy (47rd ed.). Sperryville, VA: Antimicrobial Therapy, Inc.
Fitzgerald Health Education Associates 86
Acute Pharyngitis in the Absence of URI Symptoms
References Gilbert, D., Moellering, R., Eliopoulos, G.,
Chambers, H., Saag, M. (2017) The Sanford Guide to Antimicrobial Therapy (47rd ed.). Sperryville, VA: Antimicrobial Therapy, Inc.
Wessels, M., Streptococcal PharyngitisN Engl J Med 2011; 364:648-655.
Pharyngitis withErythema or Exudate
• Offending organisms– Common bacterial
• Group A, C, G streptococcus– Uncommon bacterial
• C. diphtheriae– Classic pharyngeal and upper airway
obstruction findings
Fitzgerald Health Education Associates 88
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
14
Pharyngitis withErythema or Exudate
(continued)
• Offending organisms (cont.)– Common viruses
– In absence of URI symptoms
• Coxsackie A9, B1–5• ECHO (multiple types)• Enterovirus 71
Fitzgerald Health Education Associates 89
Pharyngitis withErythema or Exudate
(continued)• Consider sexually transmitted organisms
– Human herpes virus 1 and 2• HHV-1, HHV-2, AKA herpes simplex type 1
and 1
– N. gonorrhoeae– Primary HIV
Fitzgerald Health Education Associates 90
Exudative PharyngitisCausative Organism?
Fitzgerald Health Education Associates 91
GABHSExudative Pharyngitis with Diffuse Lymphadenopathy
Causative Organism?
Fitzgerald Health Education Associates 92
Neg for GABHS, + Monospot
Acute Pharyngitis True or false?
• Only 10% of adult pharyngitis is due to group A streptococcus.
• Vesicular, ulcerative pharyngitis is usually viral in nature.
Fitzgerald Health Education Associates 93
GABHS
• Disease in absence of pharyngitis– Erysipelas, cellulitis, and necrotizing fasciitis– Reported cause of pneumonia, toxic shock
syndrome, lymphangitis
Fitzgerald Health Education Associates 94
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
15
CellulitisSkin and Underlying Connective Tissue
ErysipelasDeep Epidermis with Lymphatic Spread
Fitzgerald Health Education Associates 95
GABHS in Exudative Pharyngitis
• 15–40% of presenting sore throats in school-aged children– Only ~10% adults
presenting with sore throat
– Less common <3 years, adult
Fitzgerald Health Education Associates 96
GABHS in Exudative Pharyngitis
(continued)
• Incubation– 3–5 day average, up to 3 months
• Transmission– Passed by saliva and nasal secretions
• Increased in crowded settings
– ? transmitted with food preparation
Fitzgerald Health Education Associates 97
Other Modes of Transmission?
• Toothbrush• Orthodontic appliance• Pets
– Usually not validated by rigorous in vivo investigation
Fitzgerald Health Education Associates 98
GABHS Pharyngitis Classic Findings
• Toxicity• Sore throat• Large, beefy tonsils• Exudate• Petechiae on palate• Lymphadenopathy• Fetid breath odor
Fitzgerald Health Education Associates 99
True or false?
• The primary rationale for therapy is eradication of Streptococcus sp. (Group A) (GAS) and prevention of acute rheumatic fever (ARF).
Fitzgerald Health Education Associates 100
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
16
True or false?
• A meta-analysis found that using only clinical diagnosis of GAS based on prediction rules without laboratory confirmation in children would lead to over treatment
– Source: J Pediatr, 160:487, 2012.
Fitzgerald Health Education Associates 101
RK11 Testing for GABHS
• Consider the following– If pharyngitis
associated rhinitis, hoarseness, or cough, likely etiology is viral; testing not necessary
Fitzgerald Health Education Associates 102
Testing for GABHS (continued)
• Preferred initial test– Rapid antigen detection test
• Routine back up throat cultures if negative streptococcus antigen not necessary for adults – Low incidence of GAS in adults and rarity of
rheumatic fever
Fitzgerald Health Education Associates 103
Intervention in Exudative Pharyngitis Adult Recommendations
• Primary– Penicillin V PO 500 mg BID or 250 mg
QID × 10 d • Or
– Benzathine penicillin 1.2 million units IM × 1 dose if adherence an issue
Fitzgerald Health Education Associates 104
Intervention in Exudative Pharyngitis Adult Recommendations
(continued)
• Alternative with history of immediate reaction to penicillin– Clindamycin 300 mg
PO q 8 h × 10 d• Consider C. difficile risk
Fitzgerald Health Education Associates 105
Intervention in Exudative Pharyngitis Adult Recommendations
(continued)
• Alternative with history of immediate reaction to penicillin– A macrolide can be used with consideration
for local patterns of GABHS resistance• Reports of ~8–20% USA GABHS isolates being
macrolide-resistant, higher in other countries– Azithromycin 500 mg day 1, 250 mg/day
days 2–5– Clarithromycin 250 mg × 10 d
Fitzgerald Health Education Associates 106
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
17
Slide 101
RK11 answer slide needed?Renee Kirshner, 8/14/2017
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
18
Do we really need to Rx 10 days of therapy for GABHS pharyngitis?
• “No therapeutic trials have verified the need for 10 days of penicillin to prevent acute rheumatic fever. The decreasing incidence of rheumatic fever in developed countries, the increasing failure rates for streptococcal eradication with penicillin, and the evidence for equivalent streptococcal eradication rates with short-course regimens (mainly cephalosporins)…”
Fitzgerald Health Education Associates 107
Do we really need to Rx 10 days of therapy for GABHS pharyngitis?
(continued)
• “…have failed to alter our faithful devotion to 10 days of penicillin for streptococcal pharyngitis. The practice has the longest lineage of any antimicrobial recommendation in clinical infectious disease and seems to be, as the author puts it, an example of ‘a more generalized phenomenon in clinical medicine, the fierce inertia of established usage.’”
– Source: Pediatr Infect Dis J 36:507, 2017)
Fitzgerald Health Education Associates 108
Intervention in Exudative Pharyngitis
• Oral cephalosporin PO for patients without immediate IgE-mediated penicillin allergy– Cephalexin 500 mg PO BID x 5 d– Cefuroxime axetil 250 mg PO BID x 5 d– Cefpodoxime proxetil 100 mg PO BID x 5 d– Cefdinir 300 mg PO q12h x 5 d or 600 mg
PO q24h x 5 d– Cefprozil 500 mg PO q24h x 5 d
Fitzgerald Health Education Associates 109
True or false?
• TMP-SMX is not recommended for the treatment of streptococcal pharyngitis due to an unacceptable rate of clinical failures.
• There are questions as to the clinical efficacy of tetracyclines including doxycycline vs. S. pyogenes.
Fitzgerald Health Education Associates 110
Intervention in Exudative Pharyngitis Pediatric Recommendations
• Penicillin V 250 mg PO BID, TID × 10 d• Or
• Amoxicillin 50 mg/kg PO daily × 10 days• Or
• Benzathine penicillin 25,000 units/kg IM (to max of 1.2 million units) × 1 dose if adherence is an issue.
Fitzgerald Health Education Associates 111
Documented S. pyogenes Recurrence
• Antimicrobial with activity against beta-lactamase producing organisms that colonize oropharynx– Amoxicillin/clavulanate– Clindamycin
Fitzgerald Health Education Associates 112
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
19
For Recurrent, Documented Bacterial GABHS Pharyngitis
• Threshold for evaluation as recurrent disease– 6 in 1 year– 4 in 2 consecutive years
• Tonsillectomy often offered with scant evidence of helpfulness
Fitzgerald Health Education Associates 113
What about…?
• No treatment recommended for asymptomatic group A streptococcus carrier
• Post treatment throat culture not recommended
Fitzgerald Health Education Associates 114
Infectivity
• Decreases 1–3 days after antibiotic started
• Return to school, daycare– Antibiotics for minimum of 24 hours – Afebrile
Fitzgerald Health Education Associates 115
Conclusion
Prescribe when neededRight med, right dose, right lengthy of time
Hold off when not needed
116Fitzgerald Health Education Associates
End of PresentationThank you for your time and attention.
Margaret A. Fitzgerald,DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC, FNAP
www.fhea.com [email protected]
Fitzgerald Health Education Associates 117
• Images/illustrations: Unless otherwise noted, all images/ illustrations are from open sources, such as the CDC or Wikipedia or property of FHEA or author.
• All websites listed active at the time of publication.
Fitzgerald Health Education Associates 118
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
20
Copyright Notice
Copyright by Fitzgerald Health Education AssociatesAll rights reserved. No part of this publication may be reproduced or transmitted
in any form or by any means, electronic or mechanical, including photocopy, recording or any information storage and retrieval system, without permission
from Fitzgerald Health Education Associates
Requests for permission to make copies of any part of the work should be mailed to:
Fitzgerald Health Education Associates85 Flagship Drive
North Andover, MA 01845-6184
Fitzgerald Health Education Associates 119
Statement of Liability
• The information in this program has been thoroughly researched and checked for accuracy. However, clinical practice and techniques are a dynamic process and new information becomes available daily. Prudent practice dictates that the clinician consult further sources prior to applying information obtained from this program, whether in printed, visual or verbal form.
• Fitzgerald Health Education Associates disclaims any liability, loss, injury or damage incurred as a consequence, directly or indirectly, of the use and application of any of the contents of this presentation.
Fitzgerald Health Education Associates 120
Fitzgerald Health Education Associates
85 Flagship Drive
North Andover, MA 01845-6154978.794.8366 Fax-978.794.2455
Website: fhea.com
Learning & Testing Center: fhea.com/npexpert
www.facebook.com/fitzgeraldhealth
@npcert
Fitzgerald Health Education Associates 121
Antibiotic Update: A focus on respiratory infections
Fitzgerald Health Education Associates. All rights reserved. Reproduction is prohibited. Prior permission required for use of questions or course content.
21